AtheroNova Inc. is a biotechnology company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans. Cardiovascular plaque reduction – the holy grail of cardiovascular research1 – is our business. Our lead compound, AHRO-001, has demonstrated remarkable plaque reduction in animals. We have shown a strong safety and tolerability profile for AHRO-001 in a Phase I clinical trial in humans. Our current corporate focus is the preparation and filing of an IND with the US Food & Drug Administration for clinical development in the United States and rest of the world. Atherosclerosis and its complications cost consumers more than $38 billion annually in the United States alone.
There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.